sabarubicin has been researched along with Cancer of Lung in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Belevich, YV; Dygai, AM; Goldberg, AV; Goldberg, VE; Miroshnichenko, LA; Polyakova, TY; Popova, NO; Simanina, EV; Simolina, EI; Tuzikova, TP; Udut, EV; Vysotskaya, VV; Zhdanov, VV; Zyuz'kov, GN | 1 |
Benzo, A; Bigioni, M; Binaschi, M; Caroli, S; Crea, A; Cubadda, F; Curatella, B; Irrissuto, C; Lopez, G; Maggi, CA; Manzini, S | 1 |
Animati, F; Arcamone, F; Berettoni, M; Bigioni, M; Capranico, G; Casazza, AM; Caserini, C; Cipollone, A; De Cesare, M; Franciotti, M; Lombardi, P; Madami, A; Manzini, S; Monteagudo, E; Polizzi, D; Pratesi, G; Righetti, SC; Salvatore, C; Supino, R; Zunino, F | 1 |
3 other study(ies) available for sabarubicin and Cancer of Lung
Article | Year |
---|---|
Assessment of Erythroid and Granulocytic Hematopoietic Lineages in Patients with Non-Small-Cell Lung Carcinoma.
Topics: Anthracyclines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cisplatin; Disaccharides; Docetaxel; Doxorubicin; Erythropoiesis; Granulocytes; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Macrolides; Nitrosourea Compounds; Organoplatinum Compounds; Taxoids | 2017 |
Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Disaccharides; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Combinations; Drug Synergism; Female; Humans; Injections, Intravenous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2008 |
Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Small Cell; Disaccharides; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Ovarian Neoplasms; Time Factors; Transplantation, Heterologous | 1997 |